Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Chen YF, Huang C, Chen ZJ, Wang ZH. Significant response to tislelizumab plus bevacizumab in a patient with microsatellite instability-high colon cancer: A case report and review of literature. World J Gastroenterol 2027; 33(2): 124393 [DOI: 10.3748/wjg.124393]
World J Gastroenterol. Jan 14, 2027; 33(2): 124393 Published online Jan 14, 2027. doi: 10.3748/wjg.124393
Significant response to tislelizumab plus bevacizumab in a patient with microsatellite instability-high colon cancer: A case report and review of literature
Yun-Fei Chen, Chi Huang, Zhi-Jian Chen, Zhi-Hui Wang
Yun-Fei Chen, Chi Huang, Zhi-Jian Chen, Zhi-Hui Wang, Department of Gastrointestinal Surgery, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China
Yun-Fei Chen, Chi Huang, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, Hubei Province, China
Co-first authors: Yun-Fei Chen and Chi Huang.
Author contributions: Chen YF was the major contributor to the writing of the manuscript; Chen YF and Huang C collected the clinical data and contributed equally as co-first authors; Chen ZJ assist in performing the surgery; Wang ZH reviewed the study. All the authors have read and approved the final manuscript.
AI contribution statement: Regarding the use of AI, generative AI tool (DeepSeek) was used solely for language editing.
Informed consent statement: Informed written consent was obtained from the patient for publication of this case report and any accompanying images. The patient has consented to the submission of the case report to the journal.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Zhi-Hui Wang, MD, PhD, Department of Gastrointestinal Surgery, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 26 Shengli Street, Jiang’an District, Wuhan 430000, Hubei Province, China. wangzhihui@tmu.edu.cn
Received: June 15, 2026 Revised: July 29, 2026 Accepted: September 15, 2026 Published online: January 14, 2027 Processing time: 147 Days and 1.8 Hours
Core Tip
Core Tip: This case report describes a rare patient with triple primary malignancies, including microsatellite instability-high/KRAS-mutated advanced colorectal cancer, with a history of clinically cured gastric and ovarian cancers, who achieved marked radiological remission following conversion therapy with tislelizumab combined with bevacizumab. The target-lesion longest diameter decreased by 72.3%, meeting Response Evaluation Criteria in Solid Tumors 1.1 criteria for a confirmed partial response. Germline testing identified a pathogenic MSH2 variant, establishing Lynch syndrome. This observation highlights the potential of combining programmed death-1 inhibitors with anti-angiogenic targeted agents in selected patients with advanced microsatellite instability-high colorectal cancer and warrants further investigation.
